MMP13 Antibody (YA6284)

MMP-13 (matrix metalloproteinase-13), also known as collagenase-3, is a zinc-dependent extracellular matrix protease that plays a central role in collagen turnover and tissue remodeling, with particularly high activity toward type II collagen, the major structural collagen of articular cartilage^[1][2]. Mechanistically, MMP-13 participates in extracellular matrix degradation by cleaving fibrillar collagens and other matrix components, thereby regulating cartilage homeostasis, skeletal development, endochondral ossification, and matrix remodeling processes^[1][3]. In disease settings, dysregulated MMP-13 expression is strongly associated with osteoarthritis (OA), where enhanced type II collagen degradation contributes directly to cartilage destruction and progressive joint pathology^[1][2][4]. Experimental studies have demonstrated that cartilage-specific overexpression of active MMP-13 induces osteoarthritis-like changes characterized by collagen cleavage, proteoglycan loss, and articular cartilage degeneration, supporting a causal role in disease progression^[2]. MMP-13 expression is regulated by inflammatory and signaling pathways, including IL-1, TNF-α, Wnt/β-catenin, TGF-β-related signaling, and other transcriptional networks that influence chondrocyte catabolism and matrix breakdown^[3][5]. Compared with related collagenases such as MMP-1 and MMP-8, MMP-13 exhibits particularly efficient cleavage of type II collagen and is considered the predominant collagenase driving cartilage degradation in OA tissues^[1][3][5]. Because of its substrate preference and disease-specific upregulation, MMP-13 has become an important therapeutic target, and selective MMP-13 inhibitors are widely used in experimental studies investigating cartilage protection and disease-modifying strategies for osteoarthritis^[3][6].